Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 4,628 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Single Dose Placebo Clear all

Conditions: Alzheimer Disease
Interventions: CMS121, Placebo; Drug
Lead sponsor: Virogenics, Inc.; Industry
Eligibility: 19 Years to 85 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Cardiovascular Disease
Interventions: INS50589 Intravenous Infusion; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Musculoskeletal Pain
Interventions: Vitamin D 2, Vitamin D2 Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Worcester, Massachusetts • St Louis, Missouri • Camden, New Jersey + 1 more

Conditions: Socioemotional Aging
Interventions: Oxytocin Spray, Placebo Spray; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Keratoconus
Interventions: Riboflavin-5-phosphate, Sham cross-linking; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 16 Years to 35 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Amherst, New York • Buffalo, New York

Conditions: Pain
Interventions: Naproxen Sodium (Aleve, BAY117031), Hydrocodone/Acetaminophen, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Behavioral Pharmacology of Cannabis
Interventions: cannabis; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: LY3023703, Placebo, Celecoxib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healthy
Interventions: Indoximod HCL (F2) tablets, Indoximod base formulation, Placebo; Drug · Other
Lead sponsor: NewLink Genetics Corporation; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Overweight, Obesity
Interventions: NNC0247-0829, Placebo (NNC0247-0829); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Subjects
Interventions: placebo, lorazepam, GW876008; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: La Jolla, California

Conditions: PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media
Interventions: Inactivated whole-cell Streptococcus pneumoniae vaccine, Placebo; Biological · Drug
Lead sponsor: Serum Life Science Europe GmbH; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Skin Irritation
Interventions: 4 placebo, 4 Vitamin D, Valchlor; Dietary Supplement · Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Glioblastoma
Interventions: Pembrolizumab, HSPPC-96, Temozolomide, Placebo, Surgery; Drug · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hereditary Angioedema
Interventions: STAR-0215 (SC), Placebo (SC), STAR-0215 (IV), Placebo (IV); Drug
Lead sponsor: Astria Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Systemic Lupus Erythematosus
Interventions: AMG 557, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 12
States / cities: Anniston, Alabama • Phoenix, Arizona • Los Angeles, California + 7 more

Conditions: Healthy Subjects
Interventions: Placebo, MEDI7814, 1 MG/KG, MEDI7814, 3 MG/KG, MEDI7814, 10 MG/KG, MEDI7814, 20 MG/KG; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Healthy
Interventions: TLL018 tablet, placebo; Drug
Lead sponsor: TLL Pharmaceutical, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Healthy
Interventions: ALXN1007, Placebo; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity
Interventions: beta3-adrenergic receptor agonist; Drug
Lead sponsor: Aaron Cypess; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a, Placebo; Drug · Other
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 36
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more

Conditions: Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid, Plasma
Interventions: LY4560736, Placebo, Florbetapir F18, Florbetaben F 18; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Anaheim, California • Irvine, California • Los Alamitos, California + 10 more

Conditions: Atrial Fibrillation
Interventions: (R)-propafenone, (S)-Propafenone, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Muscle Strength, Botulinum Toxins, Type A
Interventions: Botulinum Toxin, Type A, Saline; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 54 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Loma Linda, California

Search by objective public record fields.

Safety, Tolerability and Pharmacokinetics of CMS121, a Drug Candidate for Alzheimer's Disease, in Healthy Subjects

Study of the Tolerability, Pharmacokinetics, and Pharmacodynamics of INS50589 Intravenous Infusion in Healthy Volunteers

Vitamin D to ENhance TraUma REcovery

Faces: Choices Study

Treatment of Keratoconus Using Collagen Cross-Linking

Study to Collect Information on How Well the Study Drug Naproxen Sodium Tablets Works Compared to Hydrocodone/Acetaminophen Tablets in Order to Relieve Pain in Participants Experiencing Moderate to Severe Pain After Having Their Wisdom Teeth Removed

Differences in Cannabis Impairment and Its Measurement Due to Route of Administration

A Single Dose Study of LY3023703 in Healthy Participants

Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers

A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity

A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.

Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults

Effect of Vitamin D After Application With Valchlor

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

A Study of STAR-0215 in Healthy Adult Participants

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of TLL018, With Food Effect, in Healthy Participants

Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects

Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)

New Formulations of Propafenone to Treat Atrial Fibrillation

Assessment of the Effect of Botulinum Toxin in Extensor Digitorum Brevis Via Strain Gauge and Nerve Conduction Studies